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the A and B mutated Hoxb4 expressing progenitors had a signiﬁ-
cantly greater contribution to the PBL recovery in comparison to
Hoxb4(WT) (p  0.05). Together, these studies strongly suggest
that different intracellular levels of Hoxb4 protein are affecting
different types of hematopoietic progenitors. Early ex vivo expan-
sion of clonogenic progenitors was achieved with mutated Hoxb4
proteins without impairing HSC long-term reconstituting ability.
Thus, mutated Hoxb4 could represent a useful tool to accelerate
engraftment after HSC transplantation.
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THE USE OF RECOMBINANT HUMAN ERYTHROPOIETIN (RHUEPO)
AFTER REDUCED INTENSITY CONDITIONING (RIC) ALLOGENEIC HE-
MATOPOIETIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION
(ASCT) REDUCES RED BLOOD CELL (RBC) TRANSFUSION REQUIRE-
MENTS
Ivanov, V.1, El Cheikh, J.1, Faucher, C.1, Furst, S.1, Mohty, M.1,
Ladaique, P.1, Lemarie, C.1, Charbonnier, A.1, Coso, D.1,
Schiano, J.M.1, Viret, F.1, Blaise, D.1 1Institut Paoli-Calmettes, Mar-
seille, France.
We previously reported that hemoglobin (Hb) recovery was
hastened after RIC ASCT as compared with ASCT after myeloa-
blative conditioning (Transfusion, 44:501-8, 2004). In this setting
pretransplant Hb level becomes the major predictive factor for
early Hb recovery posttransplant and RBC transfusion (RBCT)
requirements. We subsequently reported the efﬁcacy of early
rHuEpo administration after RIC ASCT to hasten Hb reconsti-
tution (BMT, 36:901-6, 2005). Here we further conﬁrm that early
post-transplant rHuEpo after RIC reduces also RBC requirements.
40 pts surviving at least 60 days were analyzed. Pts characteristics
were as follow: age: 50 (27-64); M/F: 28/12; with myeloid (4),
lymphoid (29) or solid (7) malignancies. They received a RIC
(Fludarabin (150 mg/m; Busulfan (8mg/kg) and thymoglobulin (2.5
to 5 mg/kg)) followed with an ASCT (all PBSC) from a HLA
identical sibling. Aranesp(Amgen, France) was started on day 1.
The 20 ﬁrst pts received an infusion of 150 mcg/week while the 20
last pts were subsequently treated with 500 mcg/ 3 weeks. Aranesp-
was administered intravenously when inpatient and subcutaneously
when outpatient. Aranespadministration was sustained until day 60
or when pts reached a Hb level of 140 g/L, whichever occurred
ﬁrst. Overall pts were treated for a median of 7 weeks post trans-
plant. No serious adverse effect or thrombosis episode was re-
ported. This cohort of 40 pts experienced a quicker Hb recovery
and lower RBCT requirements than a historical and comparable
control group of 27 pts (Day 30 Hb: 114 (94-141) vs. 100
(80-129), p.0001; pts with 0 or 1 RBCT: 83% vs. 55% (p.02)).
Thirteen of the 40 pts (33%) presented with an Hb level of 120 g/L
or more prior to conditioning. Over the ﬁrst 60 days, these pts
received 0 (0-2) RBCT as compared with 1 (0-2) RBCT for pts
with a pre-RIC Hb level  120 g/L (p.05). On this basis, we
hypothesized the interest of increasing Hb level prior to RIC by
adequate rHuEpo stimulation. With this perspective, we have
treated 13 pts with Aranesp(500 mcg, SC) 3 weeks prior RIC. Nine
of these 13 pts (69%) reached an Hb level of 120 g/L or more on
day -7 as compared to 35% in patients not receiving Aranesp prior
to RIC (p.04). This indicates that Aranesppost RIC ASCT is
efﬁcient to hasten Hb recovery and decrease RBCTs. In addition,
a comprehensive strategy to minimize RBCT in this setting might
include pre-transplant stimulation. We will prospectively assess
this hypothesis.
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PROSPECTIVE ORAL MUCOSITIS AUDIT (POMA): OCCURRENCE AND
CONSEQUENCES OF SEVERE ORAL MUCOSITIS IN HIGH DOSE MELPHA-
LAN AND BEAM CONDITIONING
Blijlevens, N.1, McCann, S.2, Bacon, P.3, Quinn, B.4,
Schwenkglenks, M.5, Stone, R.6, Pico, J.7 1University Medical Centre St
Radboud, Nijmegen, Netherlands; 2St. James Hospital, Dublin, Ireland;
3Amgen International, Zug, Switzerland; 4Royal Marsden School of
Cancer Nursing and Rehabilitation, London, United Kingdom; 5Uni-
versity Hospital, Basel, Switzerland; 6Nottingham City Hospital NHS
Trust, Nottingham, United Kingdom; 7Amgen, Paris, France.
Oral mucositis (OM), an adverse effect of myeloablative reg-
imens, seriously affects patient well-being and may increase
systemic infection risk and delay recovery. Trial-based reports
of OM vary widely, with evidence of underreporting and limited
data on the incidence and impact in routine practice. Initiated
by the EGBMT, this study observed pts with multiple myeloma
(MM) or non-Hodgkin’s lymphoma (NHL) from 25 transplant
centres across 13 EU countries receiving high dose melphalan
or BEAM then autologous stem-cell transplant. Aims were to
assess duration and incidence of severe (WHO oral toxicity scale
Grade III-IV) and ulcerative (Grade II-IV) OM, resource use
for OM prevention and treatment, and associations with infec-
tion and hospitalisation duration. Prospective OM assessments
were done daily from the conditioning start to 30 days post-
transplant or hospital discharge. To achieve high and consistent
quality of assessment, nurse assessors had multimedia-assisted
face-to-face training prestudy. Of 197 evaluable pts, 110 (56%)
had MM and 87 (44%) had NHL. Mean age was 578 yrs for
MM (36% women) and 5013 yrs for NHL (51% women); 94%
had ECOG status 1. Severe OM incidence was 46% (95% CI
37-56%) for MM and 41% (95% CI 31-52%) for NHL. Severe
OM mean duration was 5.43.3d (95% CI 4.6-6.3d) in MM and
5.33.2d (95% CI 4.3-6.4d) in NHL. Ulcerative OM incidence
was 67% (95% CI 58-76%) in MM and 60% (95% CI 49-70%)
in NHL (mean duration 6.64.4d [95% CI 5.6-7.6d] and
6.53.8d [95% CI 5.6-7.7d]). WHO scale results and symptom
indicators showed similar temporal patterns (max  day 12
post-conditioning) in both groups. Clinically relevant associa-
tions with disease/conditioning type or gender were not de-
tected. A non-signiﬁcant trend hinted at an association of OM
duration with age. Fever 38°C incidence was 68% in pts with
severe OM v 47% in pts without (univariate p.004; odds ratio
2.4 [95% CI 1.3-4.4]). Mean length of staySD (truncated at
30d posttransplant) was 214d in pts with severe OM v 205d
in pts without (univariate p.023). Preliminary multivariate
analyses adjusting for other potential predictors conﬁrmed these
effects. Severe OM was a substantial clinical problem with high
dose melphalan or BEAM conditioning chemotherapy. Associ-
ations with fever occurrence and length of stay indicate poten-
tially harmful clinical sequelae and economic consequences.
Associations with conﬁrmed infection and resource use remain
to be assessed.
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COST ANALYSIS OF ALLOGENIC PERIPHERAL BLOOD TRANSPLANTA-
TION: IMPACT OF DEGREE OF MUCOSITIS AND USAGE OF PALIFERMIN
Dooley, M.J.1, Schwarer, A.1, Poole, S.G.1, Radhakrishnan, M.1,
Farag, S.1, Neville, M.2, Lee, J.2 1The Alfred, Melbourne, Victoria,
Australia; 2Pretium Pty Ltd, Sydney, New South Wales, Australia.
Background: Oral mucositis is associated with increased clinical
events and healthcare resource utilization in patients receiving
hematologic stem cell transplantation (HSCT) following myleoa-
blative therapy. Palifermin is a recombinant human keratinocyte
growth factor approved to prevent severe oral mucositis. The
impact of palifermin in the allogenic peripheral blood (PBSCT)
and the costs associated has not been quantiﬁed.
Aim: To assess the clinical and economic impact of palifermin
use in allogeneic HSCT patients.
Method:
This was a retrospective review of 21 patients undergoing allo-
genic HSCT following myeloablative chemotherapy at The Alfred
from June 2004-October 2005; versus allogeneic HSCT patients
receiving palifermin from October 2005-July 2006. We calculated
descriptive statistics on duration and grade of oral mucositis; hos-
pital length of stay (LOS), antibiotic use; antifungal use; and total
parenteral nutrition (TPN). Costs were determined through data
extracts from the hospital’s clinical costing system and through
retrospective medical record review.
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Results:
There were twenty-one patients in the historic control group.
The total cost of the hospital admissions was $AUD1,771,448
(average $AUD84,354, range $AUD28,856-276,989). Total phar-
maceutical costs for all 21 patients was $AUD 798,583, represent-
ing 45% of total costs.
Twenty (95%) patients in the historical group experienced mu-
cositis with 48% having grade 3 or 4. All ﬁve patients who received
palifermin experienced mucositis but no patients had grade 3 or 4.
The average number of TPN days was 8.3 days (median 9.5 days)
in the control group compared to 12.2 days (median 9.0 days) in
palifermin recipients. Patients that received palifermin had a mean
LOS of 34.4 days (median 25 days) compared to mean of 36.5 days
(median 35) for the control group.
Conclusion:
Palifermin usage was associated with a decreased incidence and
severity of oral mucositis with a reduction in LOS, antibiotic and
antifungal costs. Further validation of these results is required in a
larger cohort of patients.
Impact of Degree of Mucositis and Usage of Palifermin
Historical
Contol
(n21)
Palifermin
treated
group
(n5)
Mucositis any Grade - mean
days duraton
14 8
Mucositis Grade 3 or 4 -
mean days duration
3.3 0
Mucositis grade 3 or 4 - pts
(%)
11 (52.4) 0 (0)
TPN usage - mean days
duration
8 12.2
TPN usage - median days
duration
9.5 9.0
Duration of hospitalisation -
mean days
36.5 34.4
Duration of hospitalisation -
median days
35.0 25.0
Antifungal usage - mean
$AUD
$15,728 $12,854
Antifungal usage - median
$AUD
$10,720 $2,389
Total cost antibiotics,
antifungals, TPN - mean
$AUD
$20,929 $18,811
Total cost antibiotics,
antifungals, TPN -
median $AUD
$15,553 $5,605
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IMPACT OF PALIFERMIN ON HOSPITAL RESOURCE CONSUMPTION
ASSOCIATED WITH ALLOGENIC PERIPHERAL BLOOD TRANSPLANTA-
TION AND TOTAL BODY IRRADIATION
Dooley, M.J.1, Schwarer, A.1, Radhakrishnan, M.1, Poole, S.G.1,
Neville, M.A.2, Jennifer, L.2, Farag, S.1 1The Alfred, Melbourne,
Victoria, Australia; 2Pretium Pty Ltd, Sydney, New South Wales,
Australia.
Background: The impact of oral mucositis associated with au-
tologous stem cell transplantation (SCT) following high dose che-
motherapy and radiotherapy has been evaluated in the clinical trial
setting to assess the effects of palifermin. The impact of palifermin
in the allogenic peripheral blood (PBSCT) and TBI and the costs
associated has not been quantiﬁed.
Aim:
To perform an analysis of the costs associated with allogenic
PBSCT in patients who received TBI and assess the impact of oral
mucositis and palifermin.
Method:
The costs associated with patients undergoing allogenic PBSCT
and TBI following high dose chemotherapy were quantiﬁed. Consec-
utive patients who received palifermin (Oct 05-July 06) and a control
group (June 04-Oct 05) that had not were included. Costs were
determined through data extracts from the hospital’s clinical costing
system and through retrospective medical record review. Incidence,
duration and grade of mucositis, length of hospital stay (LOS), anti-
infective use and requirements for total parenteral nutrition (TPN)
were quantiﬁed.
Results:
There were eleven patients in the historic control group and ten
(91%) experienced mucositis. Five patients were evaluated in the
palifermin group and all experience mucositis. The average number of
days of oral mucositis was 8.0 days in the palifermin group compared
to 17 days in the control group. None of the palifermin treated
patients experienced grade 3 or 4 mucositis compared to 73% in the
control group who had an average duration of Grade 3-4 mucositis of
8 days (median 6 days). Patients that received palifermin had a mean
LOS of 34.4 days (median 25.0 days) compared to mean of 36.5 days
(median 28) for the control group. The average number of TPN days
with palifermin recipients was 12.2 days (median 9.0 days) compared
to 8 days (median 9 days) in the control group. For one patient who
received palifermin, TPN usage (37 days) was indicated for severe
nausea rather thanmucositis. The total costs of antibiotics, antifungals
and TPN during the period of hospitalisation was on average
$AUD18,811 (median $AUD5,606) for those patients who received
palifermin compared to $AUD18,324 (median $AUD$8,856) for
those that did not .
Conclusion:
Palifermin usage was associated with a substantial decreased
incidence and severity of oral mucositis with a reduction in LOS in
patients who received TBI with allogenic PBSCT. Further valida-
tion of these results is required in a larger cohort of patients.
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ROLE OF TRANSFUSION IN STEM CELL TRANSPLANTATION: A FREE-
DOM-FROM-TRANSFUSION (FFT), COST AND SURVIVAL ANALYSIS
Ganguly, S.1, Bradley, J.P.1, Skikne, B.S.1, Divine, C.L.1,
Deauna-Limayo, D.1, Bodensteiner, D.B.1, Patel, J.S.1 1University of
Kansas Medical Center, Kansas City, KS.
Introduction: Transfusion of blood products is often an integral
part of stem cell transplantation (SCT). Little literature exists to
deﬁne the impact of transfusion on the outcome of SCT.
Methods: In an attempt to evaluate the need and volume of
transfusion in patients undergoing SCT in our institution, we
retrospectively evaluated the records of all patients who received
SCT from 1995 till 2000.
Results:Out of 210 patients, 154 patients received autologous SCT
and 56 patients received allogeneic SCT between 1995 and 2000.
Non-Hodgkin’s lymphoma (53%) and leukemia (73%) were the most
frequent indications for autologous and allogeneic SCT respectively.
Peripheral blood stem cell (PBSC) was used in all but one patient
undergoing autologous SCT. Fifty patients received PBSC and 16
patients received bone marrow as the source of stem cells during
allogeneic SCT. One hundred thirty eight (90%) out of 154 patients
undergoing autologous SCT and 24 (43%) out of 56 patients with
allogeneic SCT exhibited total hematopoietic engraftment and free-
dom from transfusion (FFT). Time to achieve FFT in days (median;
range) for RBC units for autologous SCT (12; 0-183) was signiﬁcantly
shorter compared with allogeneic SCT (16.5; 0-373). Number of
RBC units (median; range) transfused were less in patients undergoing
autologous SCT (4; 0-26) compared with patients undergoing allo-
geneic SCT (6.5; 0-54). The median cost of transfusion was signiﬁ-
cantly higher in patients undergoing allogeneic transplantation (Red
cell: $2015; and Platelet: $4480) compared to patients undergoing
autologous transplantation (Red cell: $1240 and Platelet: $2520). The
number of transfused RBC and platelet units negatively correlated
with overall survival (median duration of follow-up: 1.3 years) in
patients with autologous SCT, but not in patients with allogeneic
SCT. This signiﬁcance remained valid in both continuous regression
analysis by Cox and dichotomous analysis (above and below median
number of transfused units) by Kaplan-Meier.
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